6 - Pharmacovigilence and Pharmacogenetics Flashcards

1
Q

What is pharmacovigilance?

A

- Pharmacovigilance is the process of identifying and then responding to safety issues about marketed drugs

  • It involves surveying the safety of drugs and developing strategies to minimise the risk and optimise benefits
  • Most common clinical adverse event is a drug reaction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the aims of pharmacovigilance?

A
  • Identify previously unrecognised drug safety hazards
  • Elucidate factors predisposing to toxicity
  • Obtain evidence of safety so that a new drug’s uses may be widened
  • ‘False positive’ adverse drug reaction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is an adverse drug reaction and what are some serious ADR’s?

A

A response that occurs in a patient to a drug, even though it has been given in the therapeutic range. Can have type A and B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are type A and type B ADRs?

A

Type A: usually a consequence of the drug’s primary pharmacological effect (e.g. bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug

  • Exaggerated pharmacological respons, predictable, dose dependent, common, high morbidity, low mortality

Type B: bizarre or novel responses that cannot be predicted from the known pharmacology of a drug

  • Not expected from known pharmacology, unpredictable, independent of dose, rare, high mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are some examples of type A and type B ADRs?

A

Type A:

  • Bleeding with warfarin
  • Hypoglycaemia with metformin

Type B:

  • Anaphylaxis with penicillin
  • Agranulocytosis with clozapine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the limitations of pre-marketing clinical studies in identifying drug safety issues?

A
  • Small number of patients treated
  • Frequent exclusion of patients who might be at greater risk of ADRs
  • Selected following precise diagnoses
  • Limited duration of treatment
  • Restricted doses

STUDY POPULATION NOT REPRESENTATIVE OF WHOLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How can we identify ADRs?

A
  • Spontaneous reporting
  • Cohort studies
  • Case control studies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the three steps involved in the spontaneous reporting of ADRs

A

⇒ Recognition of a possible ADR

⇒ Establishing possible causal relationship

⇒ Reporting observations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the advantages of spontaneous reporting?

A
  • Operates as soon as drug is marketed
  • Involves all doctors worldwide
  • Overlooks all drugs so simple
  • Inexpensive
  • Continues indefinitely
  • Accessible by all health care professionals and patients and carers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the limitations of spontaneous reporting?

A
  • Delays in reporting
  • Poor quality data
  • Misleading reports
  • No control group
  • Gross under-reporting of possible ADRs
  • Effect of publicity
  • Duplication
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the four mechanisms of action for an ADR?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the process in the UK of spontaneous reporting of ADRs?

A

Yellow Card Scheme

Report all suspected ADRs even minor ones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the factors affecting the under-reporting of ADRs?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is pharmacogenetics?

A

- Pharmacogenetics is the science of understanding how different individual genotypes relate to different drugs

  • It enables physicians to know which drugs will therefore be safe and effective for an individual patient
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is pharmacogenomics?

A

Pharmacogenomics is pharmacogenetics applied to an entire genome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the potential risk factors for drug inefficacy or toxicity?

A
  • Drug-drug interactions
  • Age
  • Renal and liver function
  • Concurrent illness

- Genetic variation have different ADRs and efficacy e.g statins and beta blockers

  • Lifestyle variables e.g. smoking and alcohol consumption
17
Q

What are some examples of split antigen hypersensitivity reactions to drugs that show genetic variation?

A
  • Abacavir for HIV treatment caused hypersensitivity in 8% of patients treated. Now screen for split antigen first
  • Carbamazepine in Asian patients was causing TEN and Stevens-Johnson syndrome
18
Q

What is the variation in genetics and the Renin-Angiotensin System?

A

An individual’s response to ACEi / ARB is dependent on their own RAS activity:

  • Young Caucasians have higher RAS activity – ACEi / ARB treatment will lower BP more effectively
  • Older and Afro-caribbean patients have lower RASS activity (renin) and angiooedema with ACEi– first line therapy is thiazide diuretics and CCBS
19
Q

5

Compare and contrast Type A and B adverse drug reactions based on the following characteristics:

  • Dose dependency
  • Predictable
  • Frequency
  • Severity
  • Host factors
  • Clinical burden
  • %ADRs
A
20
Q

Where might genetic polymorphisms affect the pharmacodynamics of a drug ?

A
  • Receptors
  • Ion channels
  • Enzymes (e.g aldehyde dehydrogenase mutated in east asian and northern european and CYPs)
  • Immune systems
21
Q

What is CYP2D6 responsible for and why is it a common CYP involved in pharmacogenetics?

A
  • Metabolises 25% of drugs including antidepressants, antipsychotics, Beta blockers, opioid analgesics
  • High genetic variability
  • 6% of Caucasians carry two null alleles for this so can’t metabolise drugs, e.g metoprolol and therefore increased amount in blood so bradycardia. Can also cause rerouting of metabolism e.g paracetamol
22
Q

Absent/reduced CYP 2D6 activity can lead to ADRs by three mechanisms. What are these mechanisms?

A
  • Decreased first pass metabolism and drug elimination e.g. metoprolol and bradycardia
  • Accumulation of drug as a result of reduced metabolism e.g. perhexilene and hepatotoxicity
  • Re-routing of metabolism e.g. paracetamol and methaemoglobinaemia
23
Q

How can we use our knowledge about a patients pharmacogenetics?

A
  • Personalise drug therapy by rapid screening of gene variants
  • Can target somatic changes in cancer
  • Can predicts ADRs, e.g statins and rhabdomyolysis